Revenue Summary of Pharma Mar, S.A.

Pharma Mar, S.A.'s latest annual revenue in 2023 was 158.15 Million EUR , down -19.45% from previous year.
Pharma Mar, S.A.'s latest quarterly revenue in 2024 Q3 was 45.65 Million EUR , up 6.49% from previous quarter.
Pharma Mar, S.A. reported a annual revenue of 196.34 Million EUR in annual revenue 2022, down -14.57% from previous year.
Pharma Mar, S.A. reported a annual revenue of 229.83 Million EUR in annual revenue 2021, down -14.87% from previous year.
Pharma Mar, S.A. reported a quarterly revenue of 37.96 Million EUR for 2024 Q1, down -6.28% from previous quarter.
Pharma Mar, S.A. reported a quarterly revenue of 45.65 Million EUR for 2024 Q3, up 6.49% from previous quarter.

Annual Revenue Chart of Pharma Mar, S.A. (2023 - 2002)

Historical Annual Revenue of Pharma Mar, S.A. (2023 - 2002)

Year	Revenue	Revenue Growth
2023	158.15 Million EUR	-19.45%
2022	196.34 Million EUR	-14.57%
2021	229.83 Million EUR	-14.87%
2020	269.96 Million EUR	214.57%
2019	85.81 Million EUR	-47.08%
2018	162.16 Million EUR	-9.58%
2017	179.33 Million EUR	-0.89%
2016	180.94 Million EUR	-6.16%
2015	192.81 Million EUR	29.68%
2014	148.68 Million EUR	5.84%
2013	140.47 Million EUR	1.63%
2012	138.22 Million EUR	-9.35%
2011	152.48 Million EUR	-0.67%
2010	153.5 Million EUR	24.41%
2009	123.38 Million EUR	17.22%
2008	105.26 Million EUR	23.17%
2007	85.45 Million EUR	12.09%
2006	76.24 Million EUR	16086.84%
2005	471 Thousand EUR	-29.6%
2004	669 Thousand EUR	-99.17%
2003	80.33 Million EUR	21.95%
2002	65.87 Million EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	42.87 Million EUR	12.92%
2024 Q1	37.96 Million EUR	-6.28%
2024 Q3	45.65 Million EUR	6.49%
2023 FY	158.15 Million EUR	-19.45%
2023 Q1	33.97 Million EUR	-38.16%
2023 Q2	46.21 Million EUR	36.0%
2023 Q3	37.45 Million EUR	-18.95%
2023 Q4	40.51 Million EUR	8.16%
2022 FY	196.34 Million EUR	-14.57%
2022 Q1	53.18 Million EUR	-38.08%
2022 Q3	39.96 Million EUR	-17.17%
2022 Q2	48.24 Million EUR	-9.28%
2022 Q4	54.94 Million EUR	37.47%
2021 Q3	45.25 Million EUR	-4.6%
2021 FY	229.83 Million EUR	-14.87%
2021 Q1	51.26 Million EUR	7.23%
2021 Q2	47.43 Million EUR	-7.47%
2021 Q4	85.88 Million EUR	89.81%
2020 Q2	69.65 Million EUR	-29.96%
2020 FY	269.96 Million EUR	214.57%
2020 Q4	47.8 Million EUR	-9.88%
2020 Q1	99.45 Million EUR	325.98%
2020 Q3	53.04 Million EUR	-23.85%
2019 Q2	21.96 Million EUR	13.0%
2019 Q4	23.34 Million EUR	10.83%
2019 Q1	19.43 Million EUR	-32.4%
2019 FY	85.81 Million EUR	-47.08%
2019 Q3	21.06 Million EUR	-4.1%
2018 Q3	26.44 Million EUR	-57.6%
2018 Q4	28.75 Million EUR	8.73%
2018 FY	162.16 Million EUR	-9.58%
2018 Q1	44.57 Million EUR	14.48%
2018 Q2	62.38 Million EUR	39.95%
2017 Q1	45.47 Million EUR	10.04%
2017 Q4	38.93 Million EUR	-10.45%
2017 Q3	43.47 Million EUR	-15.5%
2017 FY	179.33 Million EUR	-0.89%
2017 Q2	51.45 Million EUR	13.15%
2016 Q4	41.32 Million EUR	-12.98%
2016 FY	180.94 Million EUR	-6.16%
2016 Q3	47.48 Million EUR	-4.94%
2016 Q2	49.95 Million EUR	18.45%
2016 Q1	42.17 Million EUR	-36.09%
2015 FY	192.81 Million EUR	29.68%
2015 Q3	42.45 Million EUR	-14.06%
2015 Q1	34.96 Million EUR	10.03%
2015 Q2	49.4 Million EUR	41.28%
2015 Q4	65.99 Million EUR	55.44%
2014 Q4	31.77 Million EUR	-17.84%
2014 Q2	44.02 Million EUR	28.67%
2014 Q1	34.21 Million EUR	9.54%
2014 FY	148.68 Million EUR	5.84%
2014 Q3	38.67 Million EUR	-12.14%
2013 Q2	40.49 Million EUR	31.41%
2013 Q1	30.81 Million EUR	-52.93%
2013 FY	140.47 Million EUR	1.63%
2013 Q4	31.23 Million EUR	-17.67%
2013 Q3	37.93 Million EUR	-6.32%
2012 Q2	41.44 Million EUR	32.32%
2012 Q4	65.47 Million EUR	78.03%
2012 FY	138.22 Million EUR	-9.35%
2012 Q1	31.31 Million EUR	-56.0%
2012 Q3	36.77 Million EUR	-11.25%
2011 Q1	35.41 Million EUR	5.77%
2011 Q4	71.18 Million EUR	80.69%
2011 FY	152.48 Million EUR	-0.67%
2011 Q3	39.39 Million EUR	-14.15%
2011 Q2	45.88 Million EUR	29.55%
2010 FY	153.5 Million EUR	24.41%
2010 Q3	41.28 Million EUR	-9.84%
2010 Q2	45.79 Million EUR	38.99%
2010 Q1	32.94 Million EUR	16.83%
2010 Q4	33.48 Million EUR	-18.89%
2009 Q2	38.1 Million EUR	72.52%
2009 Q3	34.98 Million EUR	-8.19%
2009 Q4	28.2 Million EUR	-19.4%
2009 FY	123.38 Million EUR	17.22%
2009 Q1	22.08 Million EUR	-1.91%
2008 Q1	21.36 Million EUR	0.0%
2008 Q3	28.56 Million EUR	-12.91%
2008 FY	105.26 Million EUR	23.17%
2008 Q4	22.51 Million EUR	-21.18%
2008 Q2	32.8 Million EUR	53.52%
2007 FY	85.45 Million EUR	12.09%
2006 FY	76.24 Million EUR	16086.84%
2005 FY	471 Thousand EUR	-29.6%
2004 FY	669 Thousand EUR	-99.17%
2003 FY	80.33 Million EUR	21.95%
2002 FY	65.87 Million EUR	0.0%

Peer Revenue Comparison of Pharma Mar, S.A.

Name	Revenue	Revenue Difference
Atrys Health, S.A.	201.56 Million EUR	21.539%
Biotechnologies Assets SA	3.9 Million EUR	-3946.458%
Laboratorios Farmaceuticos Rovi, S.A.	829.5 Million EUR	80.934%

Global Stocks Search

Pharma Mar, S.A. (PHM.MC)

Revenue Summary of Pharma Mar, S.A.

Annual Revenue Chart of Pharma Mar, S.A. (2023 - 2002)

Historical Annual Revenue of Pharma Mar, S.A. (2023 - 2002)

Peer Revenue Comparison of Pharma Mar, S.A.